

**AMENDMENT TO H.R. 1919**  
**OFFERED BY MR. ENGEL OF NEW YORK**

Beginning on page 34, line 12, strike subparagraph (B) and insert the following:

1                   “(B) RETURNS EXCEPTION.—In the case  
2                   of a prescription drug product returned from a  
3                   dispenser to a wholesale distributor, the fol-  
4                   lowing applies instead of subparagraph (A):

5                               “(i) SALEABLE RETURNS.—

6                                       “(I) IN GENERAL.—Until the  
7                                       date that is one year after the date of  
8                                       the enactment of the Safeguarding  
9                                       America’s Pharmaceuticals Act of  
10                                      2013, a wholesale distributor may—

11   “(aa) accept returned pre-  
12   scription drug product without a  
13   transaction history from a dis-  
14   penser; and

15   “(bb) distribute such re-  
16   turned prescription drug product  
17   only if the wholesale distributor  
18   that so accepted the product pro-  
19   vides a transaction history that

1 begins with the wholesale dis-  
2 tributor and that includes a nota-  
3 tion that the prescription drug  
4 product is a returned prescription  
5 drug product.

6 “(II) ASSOCIATION OF TRANS-  
7 ACTION HISTORY REQUIRED AFTER 1-  
8 YEAR PERIOD.—Beginning on the  
9 date that is one year after the date of  
10 the enactment of the Safeguarding  
11 America’s Pharmaceuticals Act of  
12 2013, a wholesale distributor may dis-  
13 tribute returned prescription drug  
14 product from a dispenser only if the  
15 wholesale distributor can associate the  
16 returned prescription drug product  
17 with the applicable transaction history  
18 and transaction statement, except that  
19 the transaction history need not in-  
20 clude transaction dates if such dates  
21 are not reasonably obtainable.

22 “(ii) NONSALEABLE RETURNS.—A  
23 wholesale distributor may return a non-  
24 saleable prescription drug to the manufac-  
25 turer or repackager, to the wholesale dis-

1 tributor from whom such prescription drug  
2 was purchased, or to a person acting on  
3 behalf of such a person, including a re-  
4 turns processor, without providing the in-  
5 formation required under subparagraph  
6 (A).

